Download PDF
Thromb Haemost 1990; 64(02): 281-285
DOI: 10.1055/s-0038-1647301
Original Article
Schattauer GmbH Stuttgart

Plasminogen Activator Inhibitors Type 1 and Type 2 and Plasminogen Activators in Amniotic Fluid during Pregnancy

Amparo Estellés
1   The Research Center, Hospital “La Fe”, Valencia, Spain
,
Juan Gilabert
2   Department of Obstetrics and Gynecology, Hospital “La Fe”, Valencia, Spain
,
Cristina Andrés
1   The Research Center, Hospital “La Fe”, Valencia, Spain
,
Francisco España
1   The Research Center, Hospital “La Fe”, Valencia, Spain
,
Justo Aznar
3   Department of Clinical Pathology, Hospital “La Fe”, Valencia, Spain
› Author Affiliations
Further Information

Publication History

Received 10 January 1990

Accepted after revision18 May 1990

Publication Date:
25 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

Plasminogen activator inhibitor activity (PAI), PAI-1 and PAI-2 antigen, and other fibrinolytic parameters were evaluated in amniotic fluid during normal pregnancy and compared with that obtained in plasma of pregnant women. The results indicate the presence of both PAI-1 and PAI-2 in amniotic fluid during normal pregnancy. In amniotic fluid, PAI-1 antigen levels increased from 194 ± 109 ng/ml (first trimester) to 640 ± 396 ng/ml (third trimester) and PAI-2 antigen levels increased from 72 ± 57 ng/ml to 173 ± 97 ng/ml. In contrast, a decrease in tissue-type plasminogen activator (t-PA) antigen level was observed during pregnancy. The PAI-1 levels in amniotic fluid were significantly higher than the PAI-1 levels in plasma of women at a similar gestational age. However, PAI activity, measured using single chain t-PA, was lower in amniotic fluid than in plasma of normal pregnant women. The PAI activity/PAI-1 antigen ratio in amniotic fluid after activation by a denaturing agent increased from 0.003 ± 0.004 to 0.059 ± 0.018. These results indicate that high levels of PAI-1 are present in amniotic fluid and suggest that this PAI-1 is present in a latent form that can be reactivated, at least partially, by a denaturing agent.

 

  • References

  • 1 Wiman B, Csemiczky G, Marsk L, Robbe H. The fast inhibitor of tissue plasminogen activator in plasma during pregnancy. Thromb Haemostas 1984; 52: 124-126
    PubMedGoogle Scholar
  • 2 Lecander I, Astedt B. Isolation of a new specific plasminogen activator inhibitor from pregnancy plasma. Br J Haematol 1986; 62: 221-228
    CrossrefPubMedGoogle Scholar
  • 3 Aznar J, Gilabert J, Estellés A, España F. Fibrinolytic activity and protein C in preeclampsia. Thromb Haemostas 1986; 55: 314-7
    PubMedGoogle Scholar
  • 4 Astedt B, Lecander I, Ny T. The placental type plasminogen activator PAI-2. Fibrinolysis 1987; 1: 203-208
    PubMedGoogle Scholar
  • 5 Estellés A, Gilabert J, España F, Aznar J, Gómez-Lechón MJ. Fibrinolysis in preeclampsia. Fibrinolysis 1987; 1: 209-213
    PubMedGoogle Scholar
  • 6 Kruithof EK O, Tran-Tliang C, Gudinchet A, Havert J, Nicoloso G, Genton C, Welti H, Bachmann F. Fibrinolysis in pregnancy: A study of plasminogen activator inhibitor. Blood 1987; 69: 460-466
    PubMedGoogle Scholar
  • 7 Lecander I, Nilsson IM, Astedt B. Depression of plasminogen activator activity during pregnancy by placental inhibitor PAI-2. Fibrinolysis 1988; 2: 165-167
    PubMedGoogle Scholar
  • 8 Estellés A, Gilabert J, Aznar J, Loskutoff DJ, Schleef RR. Changes in the plasma levels of type 1 and type 2 plasminogen activator inhibitors in normal pregnancy and in patients with severe preeclampsia. Blood 1989; 74: 1332-1338
    PubMedGoogle Scholar
  • 9 Albrechtsen OD, Trolle D. A fibrinolytic system in human amniotic fluid. Acta Haematol 1955; 14: 376-382
    CrossrefPubMedGoogle Scholar
  • 10 Uszynsky M, Uszynsky-Folejewska R. Plasminogen activator and urokinase inhibitor in myometrium, placenta and amniotic fluid. Am J Obstet Gynecol 1969; 105: 1041-1043
    CrossrefPubMedGoogle Scholar
  • 11 Aznar J, Hernández A, Parrilla JJ, Estellés A, Gilabert J. Changes in amniotic fluid fibrinolytic inhibitors levels during pregnancy. Thromb Haemostas 1976; 35: 382-385
    PubMedGoogle Scholar
  • 12 Duthie JE, Campbell DM, Ogston D. Inhibition of fibrinolysis by amniotic fluid fibrinolytic inhibitor levels during pregnancy. In: Progress in Chemical Fibrinolysis and Thrombolysis Davidson JF, Samama MM, Cepelak V, Desnoyers PC. (eds) Churchill Livingstone; Edinburgh: 1979. Vol IV: pp 205-208
  • 13 Walker JE, Campbell DM, Ogston D. Inhibitors of fibrinolysis in amniotic fluid. Thromb Haemostas 1980; 44: 32-34
    PubMedGoogle Scholar
  • 14 Aznar J, Gilabert J, Estellés A, Parrilla JJ. Evaluation of plasminogen and other fibrinolytic parameters in the amniotic fluid. Thromb Haemostas 1980; 43: 182
    PubMedGoogle Scholar
  • 15 Milwidsky A, Finci Z, Mayer M. Plasminogen activator activity and urokinase inhibitor activity in human amniotic fluid and fetal membranes. Clin Biochem 1988; 21: 301-306
    CrossrefPubMedGoogle Scholar
  • 16 Kjaedgaard A, Pschera H, Larsson B, Gaffney P, Astedt B. Plasminogen activators and inhibitors in amniotic fluid. Fibrinolysis 1989; 3: 203-206
    PubMedGoogle Scholar
  • 17 Lecander I, Astedt B. Specific plasminogen activator inhibitor of placental type PAI-2 occurring in amniotic fluid and cord blood. J Lab Clin Med 1987; 110: 602-605
    PubMedGoogle Scholar
  • 18 Macart M, Gerbant L. An improvement of the Coomassie blue dye-binding method allowing an equal sensitivity to various proteins: application to cerebrospinal fluid. Clin Chim Acta 1982; 122: 93-101
    CrossrefPubMedGoogle Scholar
  • 19 DeClerck PJ, Mol MD, Alessi MC, Baudner S, Paques EP, Preissner KT, Müller-Berghaus G, Collen D. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (Vitronectin). J Biol Chem 1988; 263: 15454-15461
    PubMedGoogle Scholar
  • 20 Mimuro J, Schleef RR, Loskutoff DJ. Extracellular matrix of culture bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor. Blood 1987; 70: 721-728
    PubMedGoogle Scholar
  • 21 Creasy RK, Resnik R. Maternal-Fetal Medicine. Principles and Practice. Saunders Comp WB; Philadelphia, PA: 1984
    Google Scholar
  • 22 Colucci M, Paramo JA, Collen D. Inhibition of one-chain and two-chain forms of human tissue type plasminogen activator by the fast-acting inhibitor of plasminogen activator in vitro and in vivo. J Lab Clin Med 1986; 108: 53-59
    PubMedGoogle Scholar
  • 23 Hekman CM, Loskutoff DJ. Kinetic analysis of the interactions between plasminogen activator inhibitor 1 and both urokinase and tissue plasminogen activator. Arch Biochem Biophys 1988; 262: 199-210
    CrossrefPubMedGoogle Scholar
  • 24 Lecander I, Roblin R, Astedt B. Differential inhibition of two molecular forms of melanoma cell plasminogen activator by a placental inhibitor. Br J Haematol 1984; 57: 407-412
    CrossrefPubMedGoogle Scholar
  • 25 Hekman CM, Loskutoff DJ. Endothelial cells produce at latent inhibitor of plasminogen activators that can be activated by dénaturants. J Biol Chem 1985; 260: 11581-11587
    PubMedGoogle Scholar
  • 26 Lawrence DA, Loskutoff DJ. Inactivation of plasminogen activator inhibitor by oxidants. Biochemistry 1986; 25: 6351-6355
    CrossrefPubMedGoogle Scholar
  • 27 Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemostas Thromb 1988; 9: 87-115
    PubMedGoogle Scholar
  • 28 Kruithof EK O. Plasminogen activator inhibitor type 1: Biochemical, biological and clinical aspects. Fibrinolysis 1988; 2: 59-70
    PubMedGoogle Scholar
  • 29 Wiman B, Lindahl T, Almqvist Å. Evidence for a discrete binding protein of plasminogen activator inhibitor in plasma. Thromb Haemostas 1988; 59: 392-395
    PubMedGoogle Scholar
  • 30 Lindahl TL, Sigurdardottir O, Wiman B. Stability of plasminogen activator inhibitor 1 (PAI-1). Thromb Haemostas 1989; 62: 748-751
    PubMedGoogle Scholar
  • 31 van Mourik JA, Lawrence DA, Loskutoff DJ. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem 1984; 259: 14914-14921
    PubMedGoogle Scholar
  • 32 Erickson LA, Ginsberg MM, Loskutoff DJ. Detection and partial characterization of an inhibitor of plasminogen activator in platelets. J Clin Invest 1984; 74: 1465-1472
    CrossrefPubMedGoogle Scholar
  • 33 Philips M, Juul AG, Thorsen S, Selmer J, Zeuthen J. Immunological relationship between the fast-acting plasminogen inhibitor from plasma, blood platelets and endothelial cells demonstrated with a monoclonal antibody against an inhibitor from placenta. Thromb Haemostas 1986; 55: 213-217
    PubMedGoogle Scholar
  • 34 Lacave R, Rondeau E, Ochi S, Delarue F, Schleuning WD, Sraer JD. Characterization of a plasminogen activator and its inhibitor in human mesangial cells. Kid Intern 1989; 35: 806-811
    CrossrefPubMedGoogle Scholar
  • 35 Lind T, Kendall A, Hytten FE. The role of the fetus in the formation of amniotic fluid. J Obstet Gynaecol Br Commonw 1972; 79: 289-295
    CrossrefPubMedGoogle Scholar
  • 36 Sutcliffe RG, Brock DJ H. Immunological studies on the nature and origin of the major proteins in amniotic fluid. J Obstet Gynaecol Br Commonw 1973; 80: 721-727
    CrossrefPubMedGoogle Scholar